Clinical Trials with Dapagliflozin in Adults Dapagliflozin Dapagliflozin has been evaluated in clinical trials in adult and pediatric patients 10 years of age and older with type 2 diabetes mellitus, in adult patients with heart failure, and in adult patients with chronic kidney disease
Starting on a lower dose helps your body build tolerance, especially to stomach-related side effects such as nausea, vomiting and diarrhoea
Eli Lilly said in research studies, participants who took Foundayo lost about 25 pounds on average over 72 weeks and about 27 pounds on the highest dose, 17.2 milligrams a day, over 72 weeks
"I guess it's just quite enticing, because you're talking to people who are using it who are like, 'Oh my God, it's like transformative, and my skin's amazing, and I've lost all this weight,'" she said
Bibcode:2009PNAS..106.1285L